Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Blast Crisis 1

Interventions

fludarabine phosphate 8Cytarabine 8Peripheral Blood Stem Cell Transplantation 7Imatinib Mesylate 5Cyclophosphamide 5Busulfan 5Vorinostat 4Filgrastim 4Etoposide 4Antilymphocyte Serum 4tipifarnib 3sargramostim 3Sorafenib 3Radiotherapy 3Methylprednisolone 3Methotrexate 3Ifosfamide 3Decitabine 3Cyclosporine 3Bortezomib 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3temsirolimus 2laromustine 2belinostat 2alvocidib 2Vincristine 2Sirolimus 2Mycophenolic Acid 2Interferon-alpha 2Idarubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Blast Crisis × danusertib × Clear all
NCT00335868 2013-12-18

PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

National Cancer Institute (NCI)

Phase 2 Unknown
16 enrolled
Other hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡